Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy

Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy

Michael Bogart,1 Gary Yat-Hung Leung,2 Anissa Cyhaniuk,2 Kristi DiRocco3 1Customer Engagement, Value, Evidence and Outcomes (CEVEO) US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2STATinMED Research, Dallas, TX, USA; 3US Medical Affairs, GSK, Collegeville, PA, USACorrespondence: Kristi Di...

Full description

Bibliographic Details
Main Authors:	Bogart M, Leung GYH, Cyhaniuk A, DiRocco K
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-02-01
Series:	International Journal of COPD
Subjects:	copd initial maintenance therapy umeclidinium/vilanterol dual therapy tiotropium monotherapy hospital admissions
Online Access:	https://www.dovepress.com/inpatient-admissions-and-re-admissions-in-medicare-beneficiaries-initi-peer-reviewed-fulltext-article-COPD

Similar Items

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
by: Kerwin EM, et al.
Published: (2017-02-01)

Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model
by: Wilson MR, et al.
Published: (2017-03-01)

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
by: Miravitlles M, et al.
Published: (2016-01-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
by: Shukla S, et al.
Published: (2021-11-01)

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
by: Sethi S, et al.
Published: (2023-04-01)

Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
by: Lal C, et al.
Published: (2016-12-01)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
by: Moretz C, et al.
Published: (2020-10-01)

Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China
by: Lan Y, et al.
Published: (2022-03-01)

A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPD
by: Siler TM, et al.
Published: (2016-05-01)

The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study
by: Requena G, et al.
Published: (2021-03-01)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01)

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models
by: Ami R. Buikema, et al.
Published: (2018-10-01)

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
by: Akira Umeda, et al.
Published: (2023-04-01)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
by: Masato Muraki, et al.
Published: (2021-01-01)

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD
by: Feldman G, et al.
Published: (2016-04-01)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
by: Albertson TE, et al.
Published: (2019-06-01)

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
by: Kato M, et al.
Published: (2019-12-01)

Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States
by: Bogart M, et al.
Published: (2024-01-01)

The effectiveness of single inhaler triple therapy in patients with bronchial asthma in real clinical practice
by: V. V. Naumova, et al.
Published: (2022-04-01)

Tiotropium: a new therapeutic option in asthma
by: F. Novelli, et al.
Published: (2013-12-01)

Experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2021-01-01)

Current optimization of combined therapy for chronic obstructive pulmonary disease
by: E N Popova
Published: (2015-12-01)

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
by: Kardos P, et al.
Published: (2016-11-01)

An Open-Label, Multicentre, Observational, Post-Marketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients
by: Eun-Yeong Cho, et al.
Published: (2023-01-01)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
by: Hsieh MJ, et al.
Published: (2022-04-01)

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

Characterizing Real-World Use Of Tiotropium In Asthma In The USA
by: Averell CM, et al.
Published: (2019-10-01)

Role of Tiotropium as Step Up Therapy for Asthma
by: Muhammad Usman Ullah
Published: (2013-12-01)

The evolving role of tiotropium in asthma
by: McIvor ER, et al.
Published: (2017-08-01)

Increased treatment adherence in patients with chronic obstructive pulmonary disease when using a fixed triple combination
by: E. V. Bolotova, et al.
Published: (2021-10-01)

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
by: Wei-Chun Huang, et al.
Published: (2022-12-01)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Pharmacotherapeutic strategy for COPD patients: focus on dual bronchodilators
by: A. I. Sinopalnikov
Published: (2021-10-01)

Tiotropium in COPD: clinical outcomes and economic evidence
by: Orietta Zaniolo, et al.
Published: (2010-03-01)

Experience of using a triple fixed combination in the treatment of patients with chronic obstructive pulmonary disease
by: Elena V. Bolotova, et al.
Published: (2022-03-01)

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective
by: Schroeder M, et al.
Published: (2020-07-01)

A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
by: Bhatt SP, et al.
Published: (2017-01-01)